Creative Biolabs’ expanded primary neuron portfolio includes cortical, hippocampal, dopaminergic, and sensory neurons isolated and characterized under stringent quality control (QC) standards and ...
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results